SOLIGENIX, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
SOLIGENIX, INC. (SNGX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $360.60 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-07
- SOLIGENIX, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- SOLIGENIX, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- SOLIGENIX, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00.
- SOLIGENIX, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00.
- SOLIGENIX, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $360.60K.
- SOLIGENIX, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $347.55K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $360.60K 10-K · filed 2026-03-31 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $360.60K 10-Q · filed 2025-11-07 | ||
| 2025-06-30 | $360.60K 10-Q · filed 2026-08-07 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $0.00 derived: sum of 2 quarters · filed 2024-03-15 | $347.55K 10-K · filed 2024-03-15 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $347.55K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $347.55K 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |